Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib
IMPACT Therapeutics received approval in China in January 2025 for senaparib as first-line maintenance therapy in ovarian cancer. Credit: Jo Panuwat D / Shutterstock.com.
IMPACT Therapeutics received approval in China in January 2025 for senaparib as first-line maintenance therapy in ovarian cancer. Credit: Jo Panuwat D / Shutterstock.com.